Wearing a patch and tired of the adhesive, the sites, and the reactions? Considering a switch to a metered spray?
A patch works by sealing a reservoir of drug against your skin for 24 hours. That seal is what delivers the dose — and it is also what irritates the skin. A metered spray is applied and left to dry, with nothing worn.
Spray vs. patches: what are the differences?
Testosterone Spray Rx
RxPatch
Delivery
Testosterone Spray RxMetered transdermal spray, applied and left to dry. Powered by Hypospray®.
PatchAn adhesive system worn against the skin for 24 hours.[1]
Worn on the body
Testosterone Spray RxNo.
PatchYes — applied nightly, worn for 24 hours.[1]
Where it goes
Testosterone Spray RxA small, targeted patch of skin.
PatchBack, abdomen, upper arms or thighs — not the scrotum, not over a bony prominence, not anywhere under prolonged pressure while sleeping or sitting.[1]
Site rotation
Testosterone Spray RxNot required by a worn system.
PatchSites rotated with a seven-day interval before one is reused.[1]
Application-site reactions
Testosterone Spray RxNot an occlusive system.
PatchThe most common adverse reaction on the label — 28% overall for the 2 and 4 mg/day systems; 48% for the discontinued higher strengths.[1]
Dose adjustment
Testosterone Spray RxAt the next daily application, on your prescriber’s instruction.
PatchBy changing the system strength.[1]
Why the market moved
Testosterone Spray RxA non-occlusive route.
PatchThe literature attributes the shift to gels to "greater patient acceptability and non-occlusive nature compared with patches".[5]
PatchBilled in pieces: visits, labs, and pharmacy costs by plan.
Product details are taken from FDA labelling. The 48% application-site reaction rate belongs to Androderm’s discontinued 2.5, 5 and 7.5 mg/day strengths; the systems sold today report 28%. Keen Testosterone Spray Rx is a compounded medication prepared by a US 503A compounding pharmacy; compounded medications are not FDA-approved. Androderm is FDA-approved. Not medical advice — a licensed clinician determines whether a spray protocol is right for you.
About Testosterone Spray Rx
Testosterone Spray Rx therapies deliver compounded hormone medication through the skin using Hypospray®, a licensed topical transdermal technology. Each actuation is a metered dose, applied to a small area of clean, dry skin.
A membership covers the full loop: lab panels, licensed clinician consultations in the app, compounded medication shipped to your door, and dose adjustments made from your results.
The men’s bottle holds 14 mL and delivers 0.20 mL per spray — a 35-day supply. Your prescriber sets the per-spray strength. Pharmacokinetics for the transdermal spray platform have been published in the peer-reviewed literature.[P]
About transdermal patches
Transdermal patches were the first route to deliver testosterone through the skin — an adhesive reservoir worn against the body, releasing drug over 24 hours.
Ordinary skin is far less permeable than scrotal skin, so a non-scrotal patch needs permeation enhancers and sustained occlusion to deliver a therapeutic dose. Both irritate skin: the seal is the delivery mechanism and the irritation mechanism at once.
Androderm is applied nightly and worn for 24 hours, to the back, abdomen, upper arms or thighs, rotating sites with a seven-day interval before reusing one.[1] Its label reports application-site reactions as the most common adverse reaction — 28% overall for the 2 and 4 mg/day systems sold today, and 48% for the discontinued 2.5, 5 and 7.5 mg/day strengths, where pruritus reached 37% and blistering 12%.[1] Gels displaced patches on what the literature calls "greater patient acceptability and non-occlusive nature".[5]
See why nothing worn beats something you wear all day
One flat membership covers labs, clinicians, and medication — no per-item billing.
Patches are an established, FDA-approved route with a dose fixed by the system. These are the three reasons people most often want something else.
ONE
Nothing worn, nothing showing
No adhesive against the skin for 24 hours, and nothing visible under a shirt or at the gym.
TWO
The seal is the problem
Occlusion and permeation enhancers are how a patch gets a dose through ordinary skin — and they are why application-site reactions are the most common adverse reaction on its label.[1]
THREE
No seven-day site map
A patch label requires a seven-day interval before a site is reused.[1] A spray asks nothing of you beyond clean, dry skin.
Keen membership
Ready to stop wearing your therapy?
or $199/mo when you pay $599 up front for three months. No insurance needed.
Nothing worn on the body and nothing visible under clothing
A metered dose, applied and left to dry
No adhesive, no occlusion, no seven-day site map
Labs, clinician access, and medication in one membership
14 mL bottle, 0.20 mL per spray — a 35-day supply, with per-spray strength set by your prescriber
An FDA-approved route with a dose fixed by the system
Applied once and left alone — nothing to let dry
Familiar to clinicians and pharmacies
Application-site reactions are the most common adverse reaction on the label[1]
Sites must be rotated with a seven-day interval before one is reused[1]
What each one includes
One published membership price on our side. On the other, a bill assembled from parts.
Keen membership
$229/mo
or $199/mo when you pay $599 up front for three months. No insurance needed.
Included, no separate bill
Initial and follow-up lab panels
Licensed clinician consultations in the app
Compounded medication, shipped to your door
Dose adjustments from your lab results
Ongoing support, whenever you need it
Typical patch protocol
Varies
Billed separately
Office visits and follow-upsper visit
Lab panelsper draw
Patch medication and pharmacy feesper refill
Skin-reaction managementas needed
Replacement systems for adhesion failuresas needed
Travel and waiting-room timeper cycle
Care and support
With Keen
Licensed clinicians answer in the app — no phone tree, no separate visit fee. Lab panels, protocol changes, and refills all run through the same thread.
Patch
Support depends on the provider and the plan — office visits, pharmacy calls, and lab coordination are usually handled separately from each other.
Frequently asked questions
Is the spray inhaled or nasal?
No. Hypospray® is a topical transdermal technology — the spray is applied to your skin and absorbed through it. Nothing is inhaled.
How common are patch skin reactions really?
Androderm’s own label reports application-site reactions as the most common adverse reaction: 28% overall for the 2 and 4 mg/day systems sold today. The widely quoted 48% figure comes from the same label but describes the discontinued 2.5, 5 and 7.5 mg/day strengths, where pruritus reached 37% and blistering 12%.[1]
Why did gels replace patches?
The pharmaceutical-science literature attributes it to "greater patient acceptability and non-occlusive nature compared with patches" — comfort and convenience, not a claim about pharmacokinetics.[5]
Are patches a worse choice?
No. Patches are FDA-approved, deliver a dose fixed by the system, and the Endocrine Society guideline sets no ranking between formulations.[7] This page is about what changes in your routine and your bill if you switch.
What does membership cost?
$229/mo, or $199/mo when you pay $599 up front for three months. No insurance needed. Labs, clinician visits, and medication are included.
Spray or patch: which is right for you?
Neither route is right for everyone. A licensed clinician decides based on your labs, your history, and how you want to live with your protocol.
Consider the spray if
You have reacted to adhesives, or the site rotation has become a chore
You would rather have nothing worn on your body
You want the dose set by your prescriber rather than by the system strength
You want one predictable membership price
A patch may still suit you if
Your skin tolerates adhesives and occlusion well
You want an FDA-approved product with a dose fixed by the system
You prefer applying once and leaving it alone
The Endocrine Society guideline sets no ranking between formulations — choice rests on preference, pharmacokinetics, burden, and cost[7]
or $199/mo when you pay $599 up front for three months. No insurance needed.
Hypospray® is a registered trademark. Keen Meds Inc. utilizes the Hypospray® topical transdermal delivery platform under license.
Keen Testosterone Spray Rx is a compounded medication prepared by a US 503A compounding pharmacy; compounded medications are not FDA-approved. Products named on this page are FDA-approved and their details are taken from their FDA labelling. This is a comparison of how each medication is administered — not a claim of clinical superiority, equivalence, or comparative effectiveness. Not medical advice; a licensed clinician determines what is appropriate for you.
Dobs AS, Meikle AW, Arver S, et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate. J Clin Endocrinol Metab. 1999;84(10):3469–3478. PMID 10522982PMID 10522982
Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500–4510. PMID 11134099PMID 11134099
Kühnert B, Byrne M, Simoni M, et al. Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol. 2005;153(2):317–326. PMID 16061839PMID 16061839
Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur J Pharm Biopharm. 2015;92:42–48. PMID 25709060PMID 25709060
Schoenfeld MJ, Shortridge E, Cui Z, Muram D. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy. J Sex Med. 2013;10(5):1401–1409. PMID 23464534PMID 23464534
Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. PMID 29562364PMID 29562364
[P] Chik Z, Johnston A, Tucker AT, Chew SL, Michaels L, Alam CAS. Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone, in healthy males. Br J Clin Pharmacol. 2006;61(3):275–279. doi:10.1111/j.1365-2125.2005.02542.x PMID 16487220PMID 16487220doi:10.1111/j.1365-2125.2005.02542.x
